Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Age: Adults
Condition: Resistance or intolerance to prior therapy
Dose: Oral – 140 mg
Frequency: once daily
Note: Initial dosage. May increase to 180 mg once daily if hematologic or cytogenetic response not achieved with initial dosage.
Indication: Chronic Myeloid Leukemia (CML)
Condition: Newly diagnosed in chronic phase
Dose: Oral – 100 mg
Frequency: once daily
Note: May increase to 140 mg orally once daily if hematologic or cytogenetic response not achieved with initial dosage. Therapy was continued until disease progression or until no longer tolerated in clinical studies.

Child Dose

Clinical InformationAdministration Information
Indication: Acute Lymphoblastic Leukemia
Age: greater than 1 years
Dose: Tablet – Not recommended
Note: Begin therapy on or before day 15 of induction chemotherapy; Continue therapy for 2 years
Indication: Acute Lymphoblastic Leukemia
Age: greater than 1 years
Dose: Tablet – 40 mg
Frequency: once daily
Duration: 2 years
Note: by mouth (oral); Begin therapy on or before day 15 of induction chemotherapy

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment
Dose: Not specified
Note: No significant impact on pharmacokinetics
Administration
  • Can be taken with or without food
  • Swallow whole tablet
Side Effect

Drug Interaction

Drug NameRisk Factors
Alfentanil, cisapride, ciclosporin, fentanyl, pimozide, quinidine, simvastatin, sirolimus, tacrolimus, ergot alkaloids
May increase serum levels of these drugs
Antiplatelet drugs, Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac)
Increased risk of bleeding and thrombocytopenia

Disease Interaction

Disease NameRisk Factors
Concurrent CYP3A4 Inhibitor Use
Risk of drug interactions
Pregnancy
Risk of fetal harm

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Dasatinib tablets should be stored at 20°C to 25°C

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.